Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0IPIVC
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
ADC-C5
|
|||||
| Synonyms |
ADC C5
Click to Show/Hide
|
|||||
| Organization |
BeiGene Ltd.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 3 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
7.9
|
|||||
| Structure |
|
|||||
| Antibody Name |
Patritumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-3 (HER3)
|
Antigen Info | ||||
| Payload Name |
ADC-C5 payload
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
ADC-C5 linker
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
